Cargando…

A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole

BACKGROUND: Equine squamous gastric disease (ESGD) is a highly prevalent disease in horses, particularly in elite athletes. Some horses respond slowly, or fail to respond, to the licensed treatment, oral omeprazole (ORLO). OBJECTIVES: To compare rates of ESGD healing and improvement between ORLO and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gough, Sarah, Hallowell, Gayle, Rendle, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196684/
https://www.ncbi.nlm.nih.gov/pubmed/31945806
http://dx.doi.org/10.1002/vms3.220
_version_ 1783528760550621184
author Gough, Sarah
Hallowell, Gayle
Rendle, David
author_facet Gough, Sarah
Hallowell, Gayle
Rendle, David
author_sort Gough, Sarah
collection PubMed
description BACKGROUND: Equine squamous gastric disease (ESGD) is a highly prevalent disease in horses, particularly in elite athletes. Some horses respond slowly, or fail to respond, to the licensed treatment, oral omeprazole (ORLO). OBJECTIVES: To compare rates of ESGD healing and improvement between ORLO and a long‐acting injectable omeprazole preparation (LAIO). STUDY DESIGN: Retrospective clinical study. METHODS: The case records and gastroscopy images of horses presenting to Rainbow Equine Hospital over a 12‐month period were reviewed, with images being reviewed blind by one of the authors (David Rendle). Treatment responses were compared between horses that received 2 or 4 injections of 4 mg/kg LAIO at weekly intervals, and horses that received ORLO at 4 mg/kg PO SID for 4 weeks. Data were compared using a Mann–Whitney test with post hoc Dunn's test, chi‐squared test or Fisher's exact test. RESULTS: Fifty‐six horses met the inclusion criteria: 29 received LAIO and 27 received ORLO. Treatment groups were comparable in terms of signalment and ESGD lesions. There was a difference in rate of healing when LAIO and ORLO treatment groups were compared at 28 days (LAIO‐97%; ORLO‐67%; p = .005; OR = 14(1.8–158)), but no difference between LAIO at 14 days and ORLO at 28 days (LAIO‐86%; ORLO‐67%; p = .12; OR = 3.1 (0.9–10)). Five localised and self‐limiting injection site reactions were identified in 3 horses out of 98 injections (5.1%). MAIN LIMITATIONS: The study was limited by its retrospective nature, absence of randomisation and limited numbers. CONCLUSIONS: Four weeks of treatment with LAIO resulted in better rates of ESGD healing than 4 weeks of ORLO. Larger more robust studies of LAIO are warranted.
format Online
Article
Text
id pubmed-7196684
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71966842020-05-05 A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole Gough, Sarah Hallowell, Gayle Rendle, David Vet Med Sci Original Articles BACKGROUND: Equine squamous gastric disease (ESGD) is a highly prevalent disease in horses, particularly in elite athletes. Some horses respond slowly, or fail to respond, to the licensed treatment, oral omeprazole (ORLO). OBJECTIVES: To compare rates of ESGD healing and improvement between ORLO and a long‐acting injectable omeprazole preparation (LAIO). STUDY DESIGN: Retrospective clinical study. METHODS: The case records and gastroscopy images of horses presenting to Rainbow Equine Hospital over a 12‐month period were reviewed, with images being reviewed blind by one of the authors (David Rendle). Treatment responses were compared between horses that received 2 or 4 injections of 4 mg/kg LAIO at weekly intervals, and horses that received ORLO at 4 mg/kg PO SID for 4 weeks. Data were compared using a Mann–Whitney test with post hoc Dunn's test, chi‐squared test or Fisher's exact test. RESULTS: Fifty‐six horses met the inclusion criteria: 29 received LAIO and 27 received ORLO. Treatment groups were comparable in terms of signalment and ESGD lesions. There was a difference in rate of healing when LAIO and ORLO treatment groups were compared at 28 days (LAIO‐97%; ORLO‐67%; p = .005; OR = 14(1.8–158)), but no difference between LAIO at 14 days and ORLO at 28 days (LAIO‐86%; ORLO‐67%; p = .12; OR = 3.1 (0.9–10)). Five localised and self‐limiting injection site reactions were identified in 3 horses out of 98 injections (5.1%). MAIN LIMITATIONS: The study was limited by its retrospective nature, absence of randomisation and limited numbers. CONCLUSIONS: Four weeks of treatment with LAIO resulted in better rates of ESGD healing than 4 weeks of ORLO. Larger more robust studies of LAIO are warranted. John Wiley and Sons Inc. 2020-01-16 /pmc/articles/PMC7196684/ /pubmed/31945806 http://dx.doi.org/10.1002/vms3.220 Text en © 2020 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Gough, Sarah
Hallowell, Gayle
Rendle, David
A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole
title A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole
title_full A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole
title_fullStr A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole
title_full_unstemmed A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole
title_short A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole
title_sort study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196684/
https://www.ncbi.nlm.nih.gov/pubmed/31945806
http://dx.doi.org/10.1002/vms3.220
work_keys_str_mv AT goughsarah astudyinvestigatingthetreatmentofequinesquamousgastricdiseasewithlongactinginjectableororalomeprazole
AT hallowellgayle astudyinvestigatingthetreatmentofequinesquamousgastricdiseasewithlongactinginjectableororalomeprazole
AT rendledavid astudyinvestigatingthetreatmentofequinesquamousgastricdiseasewithlongactinginjectableororalomeprazole
AT goughsarah studyinvestigatingthetreatmentofequinesquamousgastricdiseasewithlongactinginjectableororalomeprazole
AT hallowellgayle studyinvestigatingthetreatmentofequinesquamousgastricdiseasewithlongactinginjectableororalomeprazole
AT rendledavid studyinvestigatingthetreatmentofequinesquamousgastricdiseasewithlongactinginjectableororalomeprazole